1Griffith J, Back J, Faerman C, et al. The Structural basis for auto inhibition of FLT3 by the juxtamembrane domain[ J]. Mol Cetl,2004,30 : 169 - 178.
2Stirewah DL, Radich JP. The role of FLT3 in hematopoietic mag/ignancies [ J ]. Nat Rev Cancer,2003,3 (9) :650 - 665.
3Zhang R, Baldwin BR, Levism M,et al. Co-Expression of the FLT3 recepotor and its ligand[ J]. Blood ,2001,98:90a.
4Zheng R, Friedman AD, Levis M,et al. Internal tandem duplication mutation of fit3 blocks myeloid differentiation through suppression of C/EBpot expression[ J ]. Blood ,2004,103 : 1883 - 1990.
5Chunaram Choudhary,Joachim Schwable,et al. AML-associated Fh3 kinase doma/n mutations show signal transduction differences compared with Fit3 ITD mutations[ J]. Blood,2005,106:265 - 273.
6Shih LY, Huang CF,et al, Heterogeneous patterns of Fit3 ASP835 mutations in relapsed de novo acute myeloid leukemia: a comparative analysis of 120 paired diagmostic and relapse bone marrow samplesi [J].Clinical Cancer Research ,2004,10 : 1326 - 1332.
7Rebekka Grundler, Christian Thiede, et al, Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptor[ J ]. Blood, 2003,102:646 - 651.
8Gilliand DG. Molecular genetics of Human leukemias;New insights into therapy[ J ]. Semin Hematol,2002 ,39 :6 - 11.
9Kelly LM, Kutok Jl,, Williams I R ,et al ,PMI/RARA and Flt3 1TD induce and APL-like disease in a mouse model[ J]. Proc Natl Acad Sci USA ,2002,99 : 8283 - 8288.
10Ozeki K, Kiyol H, Hirose Y ,et al, Iliologic and clinical signifieance of lhe FLT3 transcript level in acute myeloid leukemia[ J ]. Blood,2004, 103 : 1901 - 1908.
同被引文献6
1张之南,沈悌.血液学诊断与疗效标准[M].2版.北京:科学出版社,1998:214-216.
2KAINZ B, HEINTEL D, MARCULESCU R, et al. Variable prog- nostic value of FLT3 internal tandem duplications in patients with de novo AML and a normal karyotype, t(15;17), t(8;21) or inv (16) [J]. Hematol J, 2002, 3(6):283-289.
3FROHLING S, SCHLENK R F, BREITRUCK J, et al. Prognostic significance of activating FLT3 mutations in younger adults ( 16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm[ J]. Blood, 2002, 100 (13) : 4372 - 4380.
